A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumour) Cancers

Official Title

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumours

Summary:

A study to evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 alone and in Combination with Nivolumab in Advanced (Solid Tumour) Cancers

Trial Description

Primary Outcome:

  • Incidence of adverse events of BMS-986207
  • Incidence of adverse events of nivolumab (BMS-936558) and BMS-986207 when given in combination
  • Incidence of clinically significant abnormalities in general laboratory tests of BMS-986207
  • Incidence of clinically significant abnormalities in general laboratory tests of nivolumab(BMS-936558) and BMS-986207 when given in combination
Secondary Outcome:
  • Best Overall Response (BOR)
  • Objective Response Rate (ORR)
  • median Duration of Response (mDOR)
  • Progression Free Survival Rate (PFSR)
  • Maximum observed plasma concentration (Cmax) of BMS-986207
  • Time of maximum observed plasma concentration (Tmax) of BMS-986207
  • Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] of BMS-986207
  • Trough observed plasma concentration (Ctrough) of BMS-986207
  • Area under the concentration-time curve in one dosing interval [AUC(tau)] of BMS-986207
  • Total body clearance (CLT) of BMS-986207
  • Observed concentration at the end of a dosing interval (Ctau) of BMS-986207
  • Effective elimination half-life (T-HALFeff) of BMS-986207
  • Accumulation Index (AI) of BMS-986207
  • Average concentration of BMS-986207 over a dosing interval
  • Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207
  • Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207 in combination with nivolumab (BMS-936558)
  • Tumour infiltrating lymphocyte (TIL) evaluations for BMS-986207
  • Serum cytokines profiling for BMS-986207
  • Serum proteome analysis for BMS-986207
  • Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207
  • Tumour-specific immune cells for BMS-986207
  • Tumour infiltrating lymphocyte (TIL) evaluations for BMS-986207 in combination with nivolumab (BMS-936558)
  • Serum cytokines profiling for BMS-986207 in combination with nivolumab (BMS-936558)
  • Serum proteome analysis for BMS-986207 in combination with nivolumab(BMS-936558)
  • Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207 in combination with nivolumab (BMS-936558)
  • Tumour-specific immune cells for BMS-986207 in combination with nivolumab(BMS-936558)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society